Zuretinol acetate

Drug Profile

Zuretinol acetate

Alternative Names: QLT-091001; Synthetic retinaldehyde; Synthetic retinoid

Latest Information Update: 22 Dec 2016

Price : $50

At a glance

  • Originator QLT; Retinagenix LLC
  • Developer Novelion Therapeutics
  • Class Eye proteins; Retinaldehydes; Retinoids; Small molecules
  • Mechanism of Action Acyltransferase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Retinitis pigmentosa; Leber congenital amaurosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Leber congenital amaurosis; Retinitis pigmentosa
  • Phase II Nyctalopia

Most Recent Events

  • 29 Nov 2016 QLT acquired Aegerion Pharmaceuticals and later QLT changed its name to Novelion Therapeutics
  • 03 Nov 2016 Phase-III clinical trials in Leber congenital amaurosis in Denmark (PO) (EudraCT2013-005393-22)
  • 03 Nov 2016 Phase-III clinical trials in Retinitis pigmentosa in Denmark (PO) (EudraCT2013-005393-22)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top